Saskatchewan resident living with cystic fibrosis (CF) are now eligible for Trikafta, a medication that improves lung function.
Effective Nov. 15, Trikafta coverage expanded to include CF patients living with one of 152 rare genetic mutations. The medication has proven to be responsive to these mutations. Coverage expansion will include most CF patients in Saskatchewan.
"We are pleased to expand coverage for Saskatchewan people with cystic fibrosis," said Health Minister Jeremy Cockrill.
"We know Trikafta improves the quality of life for patients."
The Canadian Agency for Drugs and Technologies in Health issued a recommendation on Nov. 4 stating jurisdictions expand coverage of Trikafta for patients with 152 rare genetic mutations.
Physicians encourage patients with CF or parents/guardians of children with CF who think they may benefit from therapy with Trikafta to speak with them.
According to the Canadian Cystic Fibrosis Registry, there are more than 4,400 CF patients in Canada and more than 130 patients in Saskatchewan.
Read more: PBR Winter Classic back at Lloyd Ex
Locally owned and community driven, the Lloydminster Meridian Source is the online news source in the Border City. Whether it’s breaking news, features or sports, if you have questions about what’s going on around town, then Source it with us.
Since online platforms no longer support the sharing of news, we encourage you to bookmark meridiansource.ca. So, whether you’re having a coffee or enjoying a meal, check in any time for the most up-to-date news in Lloydminster.
